SCHEMBL5387074

SCHEMBL5387074

CCOC(=O)C(Cc1ccc(OCc2ccccc2)cc1Cl)OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
S1PR1 P21453 2/20 0.49
S1PR5 Q9H228 2/20 0.49
PRKX P51817 1/20 0.49
ACVR1 Q04771 1/20 0.49
PPARG P37231 4/20 0.45
ALDH1A1 P00352 2/20 0.45
PPARA Q07869 3/20 0.45
PPARD Q03181 1/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HSP90AA1 P07900 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
MRGPRX4 Q96LA9 2/20 0.43
MAOB P27338 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3370226 0.86 PPARA (0.52) LMNAL3MBTL1S1PR1S1PR5PRKX
SCHEMBL5391741 0.80 CYP3A4 (0.44) LMNAALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL5387612 0.79 LMNA (0.50) LMNAL3MBTL1S1PR1S1PR5PRKX
SCHEMBL5380828 0.78 PPARA (0.61) LMNAL3MBTL1PPARGALDH1A1PPARA
SCHEMBL16355724 0.78 S1PR1 (0.57) S1PR1S1PR5PRKXACVR1ALDH1A1
SCHEMBL3368391 0.76 PPARA (0.53) LMNAL3MBTL1S1PR1S1PR5PPARG
SCHEMBL2861613 0.75 MEN1 (0.62) LMNAL3MBTL1PPARGALDH1A1MEN1
SCHEMBL14392329 0.75 MMP8 (0.56) LMNAL3MBTL1PPARGALDH1A1PPARA
SCHEMBL9119394 0.75 MMP8 (0.56) LMNAL3MBTL1PPARGALDH1A1PPARA
SCHEMBL3126174 0.75 PRMT5 (0.48) LMNAL3MBTL1S1PR1S1PR5PRKX

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 US disclosed
EP-1392637-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2004-03-03 EP disclosed
WO-2002100813-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA LMNA 3747/4885L3MBTL1 3898/4885S1PR1 2395/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA LMNA 4004/4885L3MBTL1 3481/4885S1PR1 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.